Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study | Zendy

Dominik Berthold | Zendy; Gregory R. Pond | Zendy; Freidele Soban | Zendy; Ronald de Wit | Zendy; Mario A. Eisenberger | Zendy; Ian F. Tannock | Zendy

Open Access

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

Author(s) -

Dominik Berthold,

Gregory R. Pond,

Freidele Soban,

Ronald de Wit,

Mario A. Eisenberger,

Ian F. Tannock

Publication year - 2008

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2007.12.4008

Subject(s) - medicine , docetaxel , mitoxantrone , prednisone , prostate cancer , urology , survival analysis , surgery , oncology , cancer , chemotherapy

The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had occurred, showed significantly better survival and response rates for pain, prostate-specific antigen (PSA), and quality of life for D3P when compared with MP. Here, we report an updated analysis of survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research